Literature DB >> 11819602

Construction of HBV-specific ribozyme and its recombinant with HDV and their cleavage activity in vitro.

Shu Juan Wen, Kai-Jun Xiang, Zhen-Hua Huang, Rong Zhou, Xue-Zhong Qi.   

Abstract

AIM:To construct the recombinant of HDV cDNA and HBV specific ribozyme gene by recombinant PCR in order to use HDV as a transporting vector carrying HBV-specific ribozyme into liver cells for inhibiting the replication of HBV.
METHODS: We separately cloned the ribozyme (RZ) gene and recombinant DVRZ (comprising HDV cDNA and HBV-specific ribozyme gene) into the downstream of T7 promoter of pTAdv-T vector and studied the in vitro cleavage activity of their transcripts (rRZ, rDVRZ) on target RNA (rBVCF) from in vitro transcription of HBV C gene fragment(BVCF).
RESULTS: Both the simple (rRZ) and the recombinant ribozyme rDVRZ could efficiently catalyze the cleavage of target RNA (rBVCF) under different temperatures (37°, 42° and 55°) and Mg(2+) concentrations (10mmol/L, 15mmol/L and 20mmol/L) and their catalytic activity tended to increase as the temperature was rising. But the activity of rRZ was evidently higher than that of rDVRZ.
CONCLUSION: The recombinant of HDV cDNA and ribozyme gene had the potential of being further explored and used in gene therapy of HBV infection.

Entities:  

Year:  2000        PMID: 11819602      PMCID: PMC4688756          DOI: 10.3748/wjg.v6.i3.377

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  13 in total

1.  Delta virus as a vector for the delivery of biologically-active RNAs: possibly a ribozyme specific for chronic hepatitis B virus infection.

Authors:  S Y Hsieh; J Taylor
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

2.  Reversal of cisplatin resistance in vivo by an anti-fos ribozyme.

Authors:  T Funato; T Ishii; M Kanbe; K J Scanlon; T Sasaki
Journal:  In Vivo       Date:  1997 May-Jun       Impact factor: 2.155

3.  The 3'-terminal sequence of a wound tumor virus transcript can influence conformational and functional properties associated with the 5'-terminus.

Authors:  Z K Xu; J V Anzola; C M Nalin; D L Nuss
Journal:  Virology       Date:  1989-06       Impact factor: 3.616

4.  Hepatitis D virus.

Authors: 
Journal:  Rev Med Virol       Date:  1998-01       Impact factor: 6.989

5.  Repression of hepatitis B virus X gene expression by hammerhead ribozymes.

Authors:  Y K Kim; E Junn; I Park; Y Lee; C Kang; J K Ahn
Journal:  Biochem Biophys Res Commun       Date:  1999-04-21       Impact factor: 3.575

6.  An efficient 1-tube PCR method for internal site-directed mutagenesis of large amplified molecules.

Authors:  F Marini; A Naeem; J N Lapeyre
Journal:  Nucleic Acids Res       Date:  1993-05-11       Impact factor: 16.971

Review 7.  Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection.

Authors:  J R Wands; M Geissler; J Z Putlitz; H Blum; F von Weizsäcker; L Mohr; S K Yoon; M Melegari; P P Scaglioni
Journal:  J Gastroenterol Hepatol       Date:  1997-10       Impact factor: 4.029

8.  Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template.

Authors:  F von Weizsäcker; H E Blum; J R Wands
Journal:  Biochem Biophys Res Commun       Date:  1992-12-15       Impact factor: 3.575

9.  Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells.

Authors:  J Beck; M Nassal
Journal:  Nucleic Acids Res       Date:  1995-12-25       Impact factor: 16.971

10.  Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid.

Authors:  C J Hutchins; P D Rathjen; A C Forster; R H Symons
Journal:  Nucleic Acids Res       Date:  1986-05-12       Impact factor: 16.971

View more
  3 in total

1.  Methodologic research on TIMP-1, TIMP-2 detection as a new diagnostic index for hepatic fibrosis and its significance.

Authors:  Qing-He Nie; Yong-Qian Cheng; Yu-Mei Xie; Yong-Xing Zhou; Xian-Guang Bai; Yi-Zhan Cao
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

2.  Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis.

Authors:  Qing-He Nie; Guo-Rong Duan; Xin-Dong Luo; Yu-Mei Xie; Hong Luo; Yong-Xing Zhou; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

Review 3.  Progress and Prospects of Anti-HBV Gene Therapy Development.

Authors:  Mohube B Maepa; Ilke Roelofse; Abdullah Ely; Patrick Arbuthnot
Journal:  Int J Mol Sci       Date:  2015-07-31       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.